RSS
3 Jan 2023

Protalix BioTherapeutics Issues 2023 Letter to Stockholders

Author: admintech | Filed under: Press Release

CARMIEL, Israel, Jan. 3, 2023 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell…

This entry was posted on Tuesday, January 3rd, 2023 at 7:11 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»